1.77 -0.11 (-5.85%) | 02-19 15:58 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 3.05 ![]() |
1-year : | 3.71 ![]() |
Resists | First : | 2.61 ![]() |
Second : | 3.18 ![]() |
Pivot price | 1.94 ![]() |
|||
Supports | First : | 1.7 | Second : | 1.41 |
MAs | MA(5) : | 1.87 ![]() |
MA(20) : | 1.98 ![]() |
MA(100) : | 8.6 ![]() |
MA(250) : | 63.56 ![]() |
|
MACD | MACD : | -0.8 ![]() |
Signal : | -1 ![]() |
%K %D | K(14,3) : | 15.7 ![]() |
D(3) : | 14.2 ![]() |
RSI | RSI(14): 35.3 ![]() |
|||
52-week | High : | 1095 | Low : | 1.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CERO ] has closed above bottom band by 27.4%. Bollinger Bands are 95.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 2.02 - 2.03 | 2.03 - 2.04 |
Low: | 1.83 - 1.84 | 1.84 - 1.85 |
Close: | 1.86 - 1.88 | 1.88 - 1.9 |
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
Thu, 06 Feb 2025
CERo Therapeutics Holdings, Inc. Highlights Progress - GlobeNewswire
Thu, 06 Feb 2025
CERo Therapeutics strengthens cash reserves, advances clinical trials - Investing.com
Thu, 06 Feb 2025
Major Cancer Treatment Breakthrough: CERo's Next-Gen Therapy Heads to Clinical Trials with Fresh Funding - StockTitan
Wed, 05 Feb 2025
CERo's Strategic $5M Capital Raise Draws Insider Investment - StockTitan
Wed, 05 Feb 2025
CERo Therapeutics Holdings, Inc. Announces Pricing of $5 Million Public Offering to Advance Innovative T Cell Immunotherapy Programs - Nasdaq
Tue, 07 Jan 2025
Cero Therapeutics to effect 1-for-100 reverse stock split - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 3 (M) |
Shares Float | 1 (M) |
Held by Insiders | 18.7 (%) |
Held by Institutions | 4.4 (%) |
Shares Short | 573 (K) |
Shares Short P.Month | 150 (K) |
EPS | -118.56 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -4.95 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -87.6 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -8 (M) |
Levered Free Cash Flow | 8 (M) |
PE Ratio | -0.02 |
PEG Ratio | 0 |
Price to Book value | -0.38 |
Price to Sales | 0 |
Price to Cash Flow | -0.7 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |